PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31319849-8	2019	By screening beta-catenin-interacting proteins, we found that Nek2 could bind beta-catenin in sorafenib-treated HCC cell lines.	Sorafenib	94-103	NIMA related kinase 2	Homo sapiens	62-66	
31319849-0	2019	Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of beta-catenin in hepatocellular carcinoma.	Sorafenib	14-23	NIMA related kinase 2	Homo sapiens	0-4	
31319849-5	2019	Further, western blotting, flow cytometry, and an in vivo xenograft model were used to evaluate the function of Nek2 in HCC sorafenib resistance, whereas rescue experiments were performed to confirm that Nek2 induces sorafenib resistance via beta-catenin.	Sorafenib	124-133	NIMA related kinase 2	Homo sapiens	204-208	
31319849-5	2019	Further, western blotting, flow cytometry, and an in vivo xenograft model were used to evaluate the function of Nek2 in HCC sorafenib resistance, whereas rescue experiments were performed to confirm that Nek2 induces sorafenib resistance via beta-catenin.	Sorafenib	217-226	NIMA related kinase 2	Homo sapiens	204-208	
31319849-10	2019	We further confirmed that Nek2 could induce sorafenib resistance in HCC cell lines, and that beta-catenin was the key element involved in this process.	Sorafenib	44-53	NIMA related kinase 2	Homo sapiens	26-30	
31319849-11	2019	Further, a xenograft tumor model showed that Nek2 knockdown could improve the anti-tumor effect of sorafenib, whereas an analysis of tumor proteins showed that Nek2 regulates beta-catenin protein levels and its nuclear translocation in vivo.	Sorafenib	99-108	NIMA related kinase 2	Homo sapiens	45-49	
31319849-13	2019	CONCLUSIONS: Our study proves that Nek2 induces HCC sorafenib resistance via beta-catenin and suggests a novel therapeutic strategy to improve the anti-tumor effects of sorafenib in HCC.	Sorafenib	52-61	NIMA related kinase 2	Homo sapiens	35-39	
31319849-13	2019	CONCLUSIONS: Our study proves that Nek2 induces HCC sorafenib resistance via beta-catenin and suggests a novel therapeutic strategy to improve the anti-tumor effects of sorafenib in HCC.	Sorafenib	169-178	NIMA related kinase 2	Homo sapiens	35-39